Clinical Trial Update: Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update indicates henagliflozin may reduce infarct size after primary PCI in patients with ST-segment elevation myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction

Drugs mentioned

• Henagliflozin (henagliflozin)

Snippet

Sponsor: Qian geng | Conditions: Myocardial Infarction, Heart Failure | Phase 4 | Status: COMPLETED